These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 18249172)

  • 61. Hepatic NPC1L1 promotes hyperlipidemia in LDL receptor deficient mice.
    Wang Y; Tang W; Yang P; Shin H; Li Q
    Biochem Biophys Res Commun; 2018 May; 499(3):626-633. PubMed ID: 29601818
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.
    Garvey WT; Kwon S; Zheng D; Shaughnessy S; Wallace P; Hutto A; Pugh K; Jenkins AJ; Klein RL; Liao Y
    Diabetes; 2003 Feb; 52(2):453-62. PubMed ID: 12540621
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Lipid metabolism abnormalities in Chronic Kidney Disease].
    Bianchi S; Baronti A; Cominotto R; Bigazzi R
    G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960010
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet.
    Muraoka T; Aoki K; Iwasaki T; Shinoda K; Nakamura A; Aburatani H; Mori S; Tokuyama K; Kubota N; Kadowaki T; Terauchi Y
    Metabolism; 2011 May; 60(5):617-28. PubMed ID: 20673929
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Dietary phosphate restriction induces hepatic lipid accumulation through dysregulation of cholesterol metabolism in mice.
    Tanaka S; Yamamoto H; Nakahashi O; Kagawa T; Ishiguro M; Masuda M; Kozai M; Ikeda S; Taketani Y; Takeda E
    Nutr Res; 2013 Jul; 33(7):586-93. PubMed ID: 23827134
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM; Watts GF; Sprecher DL; Chan DC; Barrett PH
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Alleviating VLDL overproduction is an important mechanism for Laminaria japonica polysaccharide to inhibit atherosclerosis in LDLr
    Zha XQ; Zhang WN; Peng FH; Xue L; Liu J; Luo JP
    Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 27928899
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hepatic PTP-1B expression regulates the assembly and secretion of apolipoprotein B-containing lipoproteins: evidence from protein tyrosine phosphatase-1B overexpression, knockout, and RNAi studies.
    Qiu W; Avramoglu RK; Dubé N; Chong TM; Naples M; Au C; Sidiropoulos KG; Lewis GF; Cohn JS; Tremblay ML; Adeli K
    Diabetes; 2004 Dec; 53(12):3057-66. PubMed ID: 15561934
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sterol regulatory element-binding protein-1 determines plasma remnant lipoproteins and accelerates atherosclerosis in low-density lipoprotein receptor-deficient mice.
    Karasawa T; Takahashi A; Saito R; Sekiya M; Igarashi M; Iwasaki H; Miyahara S; Koyasu S; Nakagawa Y; Ishii K; Matsuzaka T; Kobayashi K; Yahagi N; Takekoshi K; Sone H; Yatoh S; Suzuki H; Yamada N; Shimano H
    Arterioscler Thromb Vasc Biol; 2011 Aug; 31(8):1788-95. PubMed ID: 21546605
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Low-Density Lipoprotein Receptor-Related Protein-1 Protects Against Hepatic Insulin Resistance and Hepatic Steatosis.
    Ding Y; Xian X; Holland WL; Tsai S; Herz J
    EBioMedicine; 2016 May; 7():135-45. PubMed ID: 27322467
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor.
    Johnson LA; Arbones-Mainar JM; Fox RG; Pendse AA; Altenburg MK; Kim HS; Maeda N
    Diabetes; 2011 Sep; 60(9):2285-94. PubMed ID: 21810592
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study.
    Festa A; Williams K; Hanley AJ; Otvos JD; Goff DC; Wagenknecht LE; Haffner SM
    Circulation; 2005 Jun; 111(25):3465-72. PubMed ID: 15983261
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production.
    Fisher SJ; Kahn CR
    J Clin Invest; 2003 Feb; 111(4):463-8. PubMed ID: 12588884
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance.
    Adeli K; Taghibiglou C; Van Iderstine SC; Lewis GF
    Trends Cardiovasc Med; 2001 Jul; 11(5):170-6. PubMed ID: 11597827
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Decreased lipoprotein clearance is responsible for increased cholesterol in LDL receptor knockout mice with streptozotocin-induced diabetes.
    Goldberg IJ; Hu Y; Noh HL; Wei J; Huggins LA; Rackmill MG; Hamai H; Reid BN; Blaner WS; Huang LS
    Diabetes; 2008 Jun; 57(6):1674-82. PubMed ID: 18346984
    [TBL] [Abstract][Full Text] [Related]  

  • 77. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
    Jellinger PS; Handelsman Y; Rosenblit PD; Bloomgarden ZT; Fonseca VA; Garber AJ; Grunberger G; Guerin CK; Bell DSH; Mechanick JI; Pessah-Pollack R; Wyne K; Smith D; Brinton EA; Fazio S; Davidson M
    Endocr Pract; 2017 Apr; 23(Suppl 2):1-87. PubMed ID: 28437620
    [TBL] [Abstract][Full Text] [Related]  

  • 78. SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr
    Al-Sharea A; Murphy AJ; Huggins LA; Hu Y; Goldberg IJ; Nagareddy PR
    Atherosclerosis; 2018 Apr; 271():166-176. PubMed ID: 29518749
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Knockdown expression and hepatic deficiency reveal an atheroprotective role for SR-BI in liver and peripheral tissues.
    Huby T; Doucet C; Dachet C; Ouzilleau B; Ueda Y; Afzal V; Rubin E; Chapman MJ; Lesnik P
    J Clin Invest; 2006 Oct; 116(10):2767-76. PubMed ID: 16964311
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long term hemodialysis aggravates lipolytic activity reduction and very low density, low density lipoproteins composition in chronic renal failure patients.
    Mekki K; Prost J; Remaoun M; Belleville J; Bouchenak M
    BMC Cardiovasc Disord; 2009 Aug; 9():41. PubMed ID: 19709414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.